Oral Clindamycin Research Articles

Recurrent and De Novo Toxoplasmosis Retinochoroiditis following Coronavirus Disease 2019 Infection or Vaccination.

This study reports three cases of toxoplasmosis retinochoroiditis following coronavirus disease 2019 (COVID-19) infection or vaccination from the national Canadian COVID-19 Eye Registry between December 2020 and September 2021. A 56-year-old male presented 15 days after a positive COVID-19 test with toxoplasmosis retinochoroiditis. He later relapsed 8 days following a first Pfizer-BioNTech vaccine dose. Two patients presented with toxoplasmosis retinochoroiditis following COVID-19 vaccination: A 58-year-old female presenting 4 days following a first Pfizer-BioNTech vaccine dose with anterior uveitis and a posterior pole lesion discovered 3 months later and a 39-year-old female presenting 17 days after a first Moderna vaccine dose. Resolution was achieved with oral clindamycin, oral trimethoprim/sulfamethoxazole, and topical prednisolone acetate 1%. Patients were offered prophylactic trimethoprim/sulfamethoxazole for subsequent doses without relapse. Following COVID-19 infection or vaccination, patients may be at risk for toxoplasmosis retinochoroiditis. Prophylactic antibiotics for future doses may be offered to patients with known ocular toxoplasmosis to prevent recurrence.

The effect of preoperative clindamycin in reducing early oral implant failure: a randomised placebo-controlled clinical trial

ObjectivesTo assess the effect of preoperative oral clindamycin in reducing early implant failure in healthy adults undergoing conventional implant placement.Materials and methodsWe conducted a prospective, randomised, double-blind, placebo-controlled clinical trial in accordance with the ethical principles and Consolidated Standards of Reporting Trials statement. We included healthy adults who underwent a single oral implant without previous infection of the surgical bed or the need for bone grafting. They were randomly treated with a single dose of oral clindamycin (600 mg) 1 h before surgery or a placebo. All surgical procedures were performed by one surgeon. A single trained observer evaluated all patients on postoperative days 1, 7, 14, 28, and 56. Early dental implant failure was defined as the loss or removal of an implant for any reason. We recorded the clinical, radiological, and surgical variables, adverse events, and postoperative complications. The study outcomes were statistically analysed to evaluate differences between the groups. Furthermore, we calculated the number required to treat or harm (NNT/NNH).ResultsBoth the control group and clindamycin group had 31 patients each. Two implant failures occurred in the clindamycin group (NNH = 15, p = 0.246). Three patients had postoperative infections, namely two placebo-treated and one clindamycin-treated, which failed (relative risk: 0.5, CI: 0.05–5.23, absolute risk reduction = 0.03, confidence interval: − 0.07–0.13, NNT = 31, CI: 7.2–∞, and p = 0.5). One clindamycin-treated patient experienced gastrointestinal disturbances and diarrhoea.ConclusionsPreoperative clindamycin administration during oral implant surgery in healthy adults may not reduce implant failure or post-surgical-complications.Clinical relevanceOral clindamycin is not efficacy.Trial registrationThe present trial was registered (EudraCT number: 2017-002,168-42). It was approved by the Committee for the Ethics of Research with Medicines of Euskadi (CEIm-E) on 31 October 2018 (internal code number: 201862) and the Spanish Agency of Medicines and Medical Devices (AEMPS) on 18 December 2018.

33801 Women of childbearing age with hidradenitis suppurativa frequently prescribed medications dangerous for pregnancy

Introduction: Hidradenitis suppurativa (HS) disproportionately affects women of childbearing age. In a survey of female HS patients of reproductive age, 83% reported not receiving counseling from their physician on how HS and their prescribed medications could impact childbearing. Methods: We used the National Ambulatory Medical Care Survey (NAMCS) from 2007 to 2018, the most recent years available, to quantify the treatment modalities most commonly being used for HS in women of childbearing age. Results: Oral clindamycin was the most commonly prescribed drug, followed by minocycline, trimethoprim-sulfamethoxazole (TMP-SMX), acetaminophen-oxycodone, and doxycycline. Minocycline and doxycycline are pregnancy category D and TMP-SMX and acetaminophen-oxycodone are pregnancy category C. Medications such as isotretinoin, acitretin, alitretinoin, and adalimumab were not referenced in the dataset. Discussion: As half of pregnancies in the United States are unplanned, dermatologists must consider medication safety when managing patients in this population. Oral clindamycin is not recommended unless clearly needed in the first trimester of pregnancy due to lack of data. Minocycline, doxycycline, and TMP-SMX are all well known to cause teratogenicity. It is encouraging that dermatologists are not prescribing drugs that have no indication for use during pregnancy but with relatively higher levels of efficacy evidence such as isotretinoin or alitretinoin. With the Food and Drug Administration approval of adalimumab for HS in 2018 and the increasing evidence supporting the use of biologics in HS, research should be done in order to ensure dermatologists are prescribing these medications, which are safer and more effective alternatives for women of childbearing age.

Bell's palsy with facial bone involvement: A rare presentation of chronic nonbacterial osteomyelitis with literature review.

Chronic nonbacterial osteomyelitis (CNO) is a chronic, sterile, inflammatory disease. It primarily presents with nonspecific bone pain and swelling but ultimately can cause bone destruction and deformities, if left untreated. The involvement of the cranial bones (apart from the mandible) is rare in CNO. In this report, we present a rare case of CNO affecting facial and cranial bones presenting as facial palsy with a review of the literature about similar affection. A 10-year-old, previously healthy female was initially evaluated for swelling of the left side of her face with slight tenderness on palpation, but no fever. Her complete blood count was unremarkable, her inflammatory markers were elevated (C-reactive protein 7.5 mg/dl and erythrocyte sedimentation rate 104 mm/h), and CT of facial and skull bones and MRI of brain showed a destructive osseous process involving the left maxillary, zygomatic, sphenoid bones and the clivus. Bone biopsy of the left maxilla showed fibrous dysplasia with abscess formation, most consistent with an infectious aetiology (acute osteomyelitis). She was started on oral clindamycin for a 3-month course. The facial swelling improved after starting clindamycin, but on her sixth week of treatment, she developed right-sided Bell's palsy. An MRI of the brain showed hyperenhancement of the right seventh cranial nerve. A month later, she was evaluated for right wrist and knee swelling, pain, and limitation of movement. Skeletal survey and MRI showed multifocal lesions with mixed sclerosis and lucency. Her inflammatory markers continued to be elevated. Another bone biopsy of the right radius showed similar findings of destruction with no evidence of malignancy. She was ultimately diagnosed with CNO. She was started on nonsteroidal anti-inflammatory drugs with gastric protection and regular follow-up. Over more than a year of follow-up, the patient's inflammatory markers remain normal, and joint swelling/limitation has remained in remission. We found five additional cases in the literature that presented with a similar presentation. To our knowledge, our patient is the first reported case in the USA involving the cranial/facial bones apart from the mandible presenting with facial palsy. The affection of the facial bones (apart from the mandible) in CNO is very rare, but the awareness of such a presentation by the clinician is an important aspect of reaching the diagnosis.

Erythematous scaly plaques with erosions in a 4-month-old

A 4-month-old previously healthy full-term, exclusively breastfed male infant presented with a rash on the face, arms, and diaper area for 4 weeks. The patient was previously treated by his pediatrician with nystatin cream, ketoconazole cream, hydrocortisone 2.5% ointment, and oral clindamycin without significant improvement. The family history was unremarkable. There were well-demarcated erythematous crusted plaques with focal erosions of the perioral, genital, and acral skin and scattered scaly erythematous plaques on the extremities (Fig 1, A-C).

A randomized, placebo-controlled, double-blinded trial of MRSA throat carriage treatment, with either standard decolonization alone or in combination with oral clindamycin

BackgroundStaphylococcus aureus is a frequent colonizer of the human skin and mucous membranes but can also cause a variety of serious infections. Antimicrobial resistance is an increasing worldwide challenge and is mainly driven by an overuse of antimicrobials. To avoid the spread of methicillin-resistant Staphylococcus aureus (MRSA) in Denmark, the Danish Health Authority recommends decolonization treatment of MRSA carriers and their household contacts. Standard decolonization treatment includes chlorhexidine body wash and mupirocin nasal ointment, especially throat carriage is difficult to treat. The broad-spectrum antibiotic, clindamycin, is often added to the decolonization treatment, but there is currently low scientific evidence for this treatment.AimTo investigate whether the addition of clindamycin to the standard decolonization treatment increases decolonization success in MRSA throat carriers.MethodsA randomized, placebo-controlled, double-blinded trial, including patients ≥ 18 years, who tested MRSA positive in the throat after completing one standard decolonization treatment. All carriers included in the trial receive standard decolonization treatment and are randomized to treatment with either placebo or clindamycin capsules for 10 days. We plan to include 40 participants in each of the two treatment arms.DiscussionDue to the lack of consistent scientific evidence of clindamycin’s effect in MRSA decolonization and the worldwide urgent need to reduce the use of antibiotics, we judged that a 30% increase in the decolonization success rate in carriers treated with clindamycin is appropriate to justify prescribing clindamycin as part of the decolonization treatment of asymptomatic MRSA carriers.Trial registrationEudraCT number 2019-002631-29

Is clindamycin effective in preventing infectious complications after oral surgery? Systematic review and meta-analysis of randomized controlled trials

ObjectiveTo determine the effect of clindamycin in the prevention of infection after oral surgery.Material and MethodsThis systematic review and meta-analysis followed the PRISMA statement, the PICO-framework and included only randomized controlled clinical trials. In all studies clindamycin was administered to prevent infections in patients who underwent oral surgery. Two independent researchers conducted the search, data extraction and risk of bias assessment. Included studies were classified by the type of oral surgery. Besides, data of patients, procedures and outcome variables were collected. Risk ratios (RR) and 95% confidence intervals (CI) were calculated by using Mantel–Haenszel model and the number needed to treat (NNT). Finally, any potential sources of heterogeneity were estimated.ResultsSeven trials of 540 articles met the inclusion criteria and were included in the qualitative synthesis. Four articles assessing the effect of oral clindamycin in third molar surgery were quantitatively analyzed. The overall RR was 0.66 (95% CI = 0.38–1.16), being non-statistically significant (p = 0.15). There was no heterogeneity between the studies I2 = 0, p = 0.44. The NNT was 29 (95% CI = 12- -57).ConclusionsThe effectiveness of clindamycin could not be evaluated except in third molar extraction. Oral clindamycin is ineffective in preventing infection in third molar surgery.Clinical RelevanceThere is a lack of high-quality evidence supporting the prescription of clindamycin to prevent infections after oral surgery, despite being frequently prescribed as an alternative for penicillin-allergic patients. Oral clindamycin has not been shown to be effective after third molar extractions.

A case report on the septic arthritis in a newborn: therapeutic approaches and major considerations

Introduction: The prevalence of septic arthritis (SA) is higher in underdeveloped countries than in developed countries, and the number of hospitalizations of children for this cause is decreasing and the most prevalent age group is between 0 and 4 years of age. Clinical history and detailed physical examination are essential to make an accurate diagnosis, but the neonatal period has certain limitations. Objective: To report a case of septic arthritis that occurred in a newborn admitted to the Neonatal Intensive Care Unit (ICU) due to its serious condition, morbidity, and unusual evolution of the pathology in the pediatric population, scarcity of epidemiological data on the subject, still aiming address aspects of the treatment of the disease. Case report: Male patient, born on 09/11/2020 at Santa Casa de Tupã, Sao Paulo, with a gestational age of 36 weeks and 6 days, through cesarean delivery and without complications, obtaining APGAR 9 and 10, and maintained in a room with the mother. The morning after birth, the newborn (NB) began to groan and have mild respiratory distress. The patient evolved with worsening of the breathing pattern and oxygen was concentrated at 6L/min in Hood's Halo, presenting hyperthermia, hyperemia, and edema in the right elbow. Laboratory tests showed an increase in C-Reactive Protein and worsened hematimetric indices of the blood count, and antibiotic therapy was then started with oxacillin 50 mg/kg/dose and amikacin 15 mg/kg/day. The ultrasound of the right elbow showed skin thickening, absence of collections, and no changes in vasculature, being suggestive of cellulite. A new ultrasound of the right elbow showed bulging, intra-articular collection, and discreet collection with extra-articular communication in the medial region, being suggestive of septic arthritis. Blood culture collection resulted in the growth of gram-positive cocci (Staphylococcus aureus) in a pair of samples. The patient received intravenous treatment with Vancomycin for 14 days with clinical and laboratory improvement of the infection and was discharged with the use of oral Clindamycin for another 14 days and physical therapy follow-up for rehabilitation of movement of the affected limb. Final considerations: Due to the unusual evolution of SA in the neonatal period, and the scarcity of literature on the pathology in this age group, the importance of further studies on the subject, and greater surveillance for neonatal diagnosis, in addition to early treatment to reduce of complications.

Efficacy of 3-day low dose quinine plus clindamycin versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children (CLINDAQUINE): an open-label randomized trial

BackgroundThe World Health Organization recommends quinine plus clindamycin as first-line treatment of malaria in the first trimester of pregnancy and as a second-line treatment for uncomplicated falciparum malaria when artemisinin-based drug combinations are not available. The efficacy of quinine plus clindamycin was compared with that of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in children below 5 years of age.MethodsAn open-label, phase 3, randomized trial was conducted in western Kenya. Children aged 6–59 months with uncomplicated falciparum malaria were randomly assigned (1:1) via a computer-generated randomization list to receive 3 days of twice a day treatment with either oral quinine (20 mg/kg/day) plus clindamycin (20 mg/kg/day) or artemether-lumefantrine (artemether 20 mg, lumefantrine 120 mg) as one (for those weighing 5–14 kg) or two (for those weighing 15–24 kg) tablets per dose. The primary outcome was a PCR-corrected rate of adequate clinical and parasitological response (ACPR) on day 28 in the per-protocol population.ResultsOf the 384 children enrolled, 182/192 (94.8%) receiving quinine plus clindamycin and 171/192 (89.1%) receiving artemether-lumefantrine completed the study. The PCR-corrected ACPR rate was 44.0% (80 children) in the quinine plus clindamycin group and 97.1% (166 children) in the artemether-lumefantrine group (treatment difference − 53.1%, 95% CI − 43.5% to − 62.7%). At 72 h after starting treatment, 50.3% (94 children) in the quinine plus clindamycin group were still parasitaemic compared with 0.5% (1 child) in the artemether-lumefantrine group. Three cases of severe malaria were recorded as serious adverse events in the quinine plus clindamycin group.ConclusionsThe study found no evidence to support the use of a 3-day low dose course of quinine plus clindamycin in the treatment of uncomplicated falciparum malaria in children under 5 years of age in Kenya, where artemether-lumefantrine is still effective.Trial Registration: This trial is registered with the Pan-African Clinical Trials Registry, PACTR20129000419241.

Microbiome Resilience despite a Profound Loss of Minority Microbiota following Clindamycin Challenge in Humanized Gnotobiotic Mice.

ABSTRACTAntibiotics are known to induce gut dysbiosis and increase the risk of antibiotic resistance. While antibiotic exposure is a known risk factor leading to compromised colonization resistance against enteric pathogens such as Clostridioides difficile, the extent and consequences of antibiotic perturbation on the human gut microbiome remain poorly understood. Human studies on impacts of antibiotics are complicated by the tremendous variability of gut microbiome among individuals, even between identical twins. Furthermore, antibiotic challenge experiments cannot be replicated in human subjects for a given gut microbiome. Here, we transplanted feces from three unrelated human donors into groups of identical germfree (GF) Swiss-Webster mice, and examined the temporal responses of the transplanted microbiome to oral clindamycin challenge in gnotobiotic isolators over 7 weeks. Analysis of 177 longitudinal fecal samples revealed that 59% to 81% of human microbiota established a stable configuration rapidly and stably in GF mice. Microbiome responses to clindamycin challenge was highly reproducible and microbiome-dependent. A short course of clindamycin was sufficient to induce a profound loss (∼one third) of the microbiota by disproportionally eliminating minority members of the transplanted microbiota. However, it was inadequate to disrupt the global microbial community structure or function, which rebounded rapidly to resemble its pre-treatment state after clindamycin discontinuation. Furthermore, the response of individual microbes was community-dependent. Taken together, these results suggest that the overall gut microbiome structure is resilient to antibiotic perturbation, the functional consequences of which warrant further investigation.IMPORTANCE Antibiotics cause imbalance of gut microbiota, which in turn increase our susceptibility to gastrointestinal infections. However, how antibiotics disrupt gut bacterial communities is not well understood, and exposing healthy volunteers to unnecessary antibiotics for research purposes carries clinical and ethical concerns. In this study, we used genetically identical mice transplanted with the same human gut microbiota to control for both genetic and environmental variables. We found that a short course of oral clindamycin was sufficient to eliminate one third of the gut bacteria by disproportionally eliminating minority members of the transplanted microbiota, but it was inadequate to disrupt the overall microbial community structure and function, which rebounded rapidly to its pre-treatment state. These results suggest that gut microbiome is highly resilient to antibiotic challenge and degradation of the human gut ecosystem may require repeated or prolonged antibiotic exposure.

Reactivation of Dormant Tibial Methicillin- Resistant Staphylococcus aureus Osteomyelitis after 17 Years: A Case Report and Literature Review

Introduction: Staphylococcus aureus is the most common cause of osteomyelitis with significant morbidity and mortality outcomes. Methicillin-susceptible Staphylococcus aureus (MRSA) osteomyelitis reactivation years after the primary episode are a well-known phenomenon. However, there are few case reports documenting dormant MRSA osteomyelitis recurrence years later. Our case report of dormant MRSA tibial osteomyelitis reactivation after 17-years, represents one of the longest documented recurrence intervals from initial bout of MRSA, as well as, the diagnostic and therapeutic challenges involved. Case report: A 55-year-old male reports suffering a Gustilo & Anderson grade 1 open left tibial plafond fracture in 2004 that was managed with wound debridement and Taylor Spatial Frame. Initial management was with debridement and primary closure of the wound and application of a Taylor spatial frame (TSF) as definitive management of the fracture. One month following application of the frame, the patient reports he suffered a pin site infection. This was developed into MRSA osteomyelitis. The wound underwent surgical debridement and once the fracture was consolidated enough at three months, removal of external frame and intramedullary reaming and irrigation was performed. No further soft tissue coverage was required. The patient was treated with a prolonged course of intravenous vancomycin, followed by oral clindamycin. Since this episode, the patient has been asymptomatic and denied any further hospitalisations with return to full function without limitations. The patient does not report any recurrent wounds, discharge, sinus or pain. Seventeen years later, after a closed to the knee, the patient present febrile with knee pain. He was found to have MRSA tibial osteomyelitis, predominantly within the proximal tibia. This was treated with targeted surgical debridement, local antibiotics via an antibiotic impregnated cement nail and prolonged antibiotics. The patient has remained asymptomatic with apparent resolution of infection 6-months post treatment. Conclusion: Our case report represents one of the longest document recurrence intervals of MRSA. Patients with MRSA osteomyelitis should have appropriate treatment and follow-up with orthopaedic surgeons and infectious disease physicians to monitor disease progression and to ensure resolution of the infection.

Recurrent Toxoplasma Retinitis Treated with Long-Term Oral Antibiotics

Purpose: The purpose of this case was to report the inhibition of toxoplasma retinitis reactivation with long-term, low-dose antibiotics.Case summary: A 76-year-old woman complained of poor vision and floaters in her right eye. The corrected visual acuity (LogMAR) of the right eye was 0.5, and there was an area of yellow infiltration and dye leakage on the retinal fluorescein angiography images. Toxoplasma IgG were detected in the serum, the patient was diagnosed with toxoplasma retinitis, and the patient was advised oral trimethoprim-sulfamethoxazole, clindamycin, and steroids. Her visual acuity improved and the inflammation resolved. However, she again had decreased visual activity and retinal inflammation in her right eye after 5 months. The inflammation improved with oral steroids, but she was shifted to intravitreal dexamethasone because of the side effects of systemic steroids. Although the inflammation improved initially, there was worsening of inflammation (evidenced by vitreous opacity) after 2 months, which was treated with oral antibiotics. After vitrectomy for the removal of residual vitreous opacity, antibiotics were stopped because of the stable disease course. After discontinuation of the antibiotics, inflammation was noted again, and low-dose trimethoprim-sulfamethoxazole was administered. Low-dose antibiotics were continued for 5 months and the disease remained stable without any retinal inflammation.Conclusions: Long-term, low-dose oral antibiotics may prevent reactivation of recurrent toxoplasma retinitis.

Comparative study of surgical site infection with or without post cesarean prophylactic oral antibiotics; a single-blinded randomized clinical trial

Introduction: Surgical site infection (SSI) is caused by cesarean section in the hospital and its prevalence in the studies is up to 16%. Objectives: This study aimed to compare the rate of infection in women undergoing cesarean section. Oral clindamycin and cefalexin were administered for 48 hours as prophylactic antibiotics. Patients and Methods: In this clinical trial study, women with emergency cesarean section were divided into two groups. Intervention was oral administration of cefalexin 500mg every 6 hours and clindamycin 300 mg every 6 hours for 48 hours. All participants were referred to the gynecology center on day 7–10, at the time of removal of the sutures, and within 30 days after cesarean section, to assess the presence or absence of wound infection after surgery during 30 days. Results: In this clinical trial study, 462 pregnant women undergoing cesarean section were enrolled in the intervention and control groups. Of 231 patients in the intervention group, 15 women (6.5%) had cesarean section infection (13 cases with superficial, and 2 cases with deep infection). In the control group, 45 cases (19.5%) had cesarean section infection (31 cases with superficial, 10 cases with deep, and 4 cases with developed pelvic infection) (P = 0.001). Age, pre-cesarean length of stay, pre-term incision, type of incision, discharge longer than 18 hours after cesarean section, and maternal diabetes were significantly different regarding cesarean section infection in both groups. The frequency of cesarean section infection was less in the intervention group (P <0.001). Conclusion: Administration of prophylactic antibiotic can have a significant role in reducing cesarean section infection. Trial Registration: Registration of trial protocol has been approved in Thailand registry of clinical trials (identifier: TCTR20201204002, http://www.clinicaltrials.in.th/index.php?tp=regtrials & menu=trialsearch & s-menu=fulltext & task=search & task2=view1 & id=7120, ethical code; IR.UMSU.REC.1397.323).

064 Short-term intravenous clindamycin accelerates the benefit of oral clindamycin-rifampicin treatment in hidradenitis suppurativa (HS)

A 10-to-12-week course of combined clindamycin/rifampicin or tetracyclines are the first-line medical treatment for moderate-to-severe HS. A recent multicenter European study revealed significant efficacy of oral clindamycin/rifampicin and tetracyclines without differences between them, independently of baseline HS severity. Our study explored the efficacy of a treatment induction with a 5-day loading dose of i.v. clindamycin (3x600 mg/d) prior to the oral clindamycin/ rifampicin combination, in 95 consecutive, previous treatment-naive adult HS patients.

Comparative Effectiveness of Treatments for Bacterial Vaginosis: A Network Meta-Analysis

Bacterial vaginosis (BV) is a common vaginal dysbiosis in women of reproductive age. However, the cure rate for BV varies considerably and many women experience a relapse after the initial treatment. The present meta-analysis aimed to evaluate the clinical cure rates (CCRs) in randomized controlled trials (RCTs) through different therapies and administration routes. This meta-analysis included a final set of 25 eligible studies with a total of 57 RCTs and compared the effectiveness of BV treatments among non-pregnant and pregnant women. The initial range of CCRs varied greatly from 46.75% to 96.20% and the final pooled CCR was 75.5% (CI: 69.4–80.8) using the random model. The heterogeneity indices were Q = 418.91, I2 = 94.27%, and τ = 0.7498 (p < 0.0001). No publication bias was observed according to Funnel plot symmetry and Egger’s linear regression test (p = 0.1097). To evaluate different variables, sub-group analysis, meta-regressions, and network meta-analysis were also realized. The highest P-scores in CCR were obtained by: (1) a combined therapy with local probiotic treatment and application of antibiotics by both administration route (oral clindamycin and local 5-nitroimidazole; P-score = 0.92); (2) a combined therapy with oral administration of 5-nitroimidazole and probiotic treatment (P-score = 0.82); (3) and a combined therapy with local administration of 5-nitroimidazole and oral probiotic treatment (P-score = 0.68). A clear-cut decision of the best BV treatment was not possible due to the heterogeneity of outcomes reported in the trials, indicating the necessity for a better characterization of RCTs. Finally, combined therapies suggested the reduction of the optimal concentration of antibiotics, and double phase treatments of antibiotics indicated an increment of CCRs in BV.

Evaluation of embryotoxicity and fetotoxicity of Clindamycin phosphate under normal and elevated levels of serum Hydrogen sulfide in rats

Widespread use of antibiotics in clinical practice leads to the development of antibiotic resistance and encourages the search for new ways of modulation of their therapeutic effect. One of the potentially successful modulators may be Hydrogen sulfide, but the mechanisms of its action require careful studies, including toxicological. The aim of the study was to study the effect of Hydrogen sulfide levels on the embryotoxicity and fetotoxicity of oral and intravaginal Clindamycin phosphate administration. The experimental study was performed on 60 pregnant female rats, which were divided into 6 experimental groups: group 1 – control group; group 2 – high level of serum Hydrogen sulfide; group 3 – Clindamycin phosphate intravaginally; group 4 – Clindamycin phosphate intravaginally with high level of serum Hydrogen sulfide; group 5 – Clindamycin phosphate orally; group 6 – Clindamycin phosphate orally with high level of serum Hydrogen sulfide. We studied the dynamics of weight gain in pregnant rats, the number of corpora lutea, the number of implantation sites in the uterus, the number of live and dead fetuses, preimplantation and postimplantation mortality, as well as the dynamics of body weight gain and mental development of offspring. Artificially increasing the serum level of Hydrogen sulfide in pregnant rats led to an increase in maternal weight gain, an increase in the weight and cranio-caudal size of embryos, as well as a decrease in the number of resorbed fetuses and postimplantation mortality. The insignificant toxic effect of high doses of oral Clindamycin phosphate was leveled in the group with elevated indices of serum Hydrogen sulfide. Rats born to females with elevated levels of serum Hydrogen sulfide showed faster rates of weight gain and normal mental development according to the “open field” test.

Investigating auranofin for the treatment of infected diabetic pressure ulcers in mice and dermal toxicity in pigs

Bacterial infection of pressure ulcers (PUs) are a notable source of hospitalization for individuals with diabetes. This study evaluated the safety profile and efficacy of auranofin to treat diabetic PUs infected with methicillin-resistant Staphylococcus aureus (MRSA). PUs were infected with MRSA in diabetic TALLYHO/JngJ mice and then treated with topical auranofin (2%), topical mupirocin (2%), or oral clindamycin (30 mg/kg) for four days. PUs were harvested post-treatment to enumerate bacterial burden and determine expression of cytokines/growth factors. Landrace cross pigs were exposed topically to auranofin (1%, 2%, and 3%) for 4–14 days and evaluated for signs of localized or systemic toxicity. Auranofin eradicated MRSA in PUs within four days (7.92-log10 reduction) in contrast to mupirocin (2.15-log10 reduction) and clindamycin (0.73-log10 reduction). Additionally, auranofin treatment resulted in decreased expression of pro-inflammatory cytokines and increased expression of biomarkers associated with re-epithelization of wounded tissue, confirmed with histopathologic analysis. No significant histopathologic lesions were present on porcine skin sites exposed to topical auranofin. Additionally, minimal accumulation of plasma gold and no systemic toxicity was observed in pigs exposed to topical auranofin. Auranofin appears to be a potent and safe topical agent to further investigate for treatment of mild-to-moderate MRSA-infected diabetic PUs.

Systemic antibiotics in hidradenitis suppurativa: efficacy and effects of body mass index and smoking pack-year on the response to therapy.

The combination of oral clindamycin with rifampicin is recommended by European guidelines as a first-line treatment in moderate-to-severe hidradenitis suppurativa (HS). Recent studies highlight that oral clindamycin in monotherapy (CM) may be a useful alternative treatment. We included 36 patients with a diagnosis of moderate-to-severe HS. A total of 19 patients were treated with combination oral clindamycin plus rifampicin (C + R) and 17 with oral CM for 12 weeks. The efficacy of CM vs C + R was analyzed by multilinear regression models which showed a higher reduction in mSartorius (Δ = -13.2, P = .058) and AISI (Δ = -4.91, P = .034) in the C + R group. In the C + R group, smoking pack-year was positively correlated with AISI (Spearman's rho = 0.51, P = .036) and with DLQI (0.47, P = .061). In the CM group, a positive correlation was found between BMI and AISI (0.47, P = .041). The data on the efficacy of C + R combination therapy are in line with guidelines, evidence-based approaches, and recommendations from the HS ALLIANCE working group. The rationale for combining these two drugs is to increase bactericidal action and to reduce rifampicin resistance, as rifampicin is highly mutagenic. Our results suggest that the antibiotic combination of C + R is still the treatment of choice in moderate-to-severe HS with abscesses, draining fistulae and ≥ 5 inflammatory nodules. High BMI and smoking habits seem to be predictive factors of a poor response to antibiotics. Further multicenter studies and prospective randomized controlled trials are needed to confirm these results. Potential alternative antibiotic therapies should also be investigated.

An Unusual Case of Chest Pain in a 9-Year Old Immigrant

CASE PRESENTATION: A nine-year-old female with no past medical history presented to the emergency department with a two-week history of chest pain associated with tactile fevers and cough. One-year prior, she traveled by foot from Venezuela to the United States crossing through five countries and was detained in both Panama and the U.S. border prior to arriving in Atlanta four months ago. On physical exam, she appeared thin and emaciated, with decreased breath sounds on the right, but otherwise was in no respiratory distress with normal oxygen saturations. Initial work-up revealed leukocytosis, normocytic anemia, elevated inflammatory markers, and a normal blood smear. Chest X-Ray showed a dense opacity of the right upper lobe with mass effect of the right main stem bronchus (Image 1). Subsequent CT scan was notable for a large cavitary lesion of the right upper lobe concerning for abscess (Image 2) with hilar lymphadenopathy and a small spleen. She was empirically started on vancomycin and ceftriaxone but narrowed to clindamycin after sputum culture grew MRSA. One week into hospitalization, her anemia worsened, prompting a hemoglobin electrophoresis test, which revealed the delayed diagnosis of hemoglobin SS disease complicated by acute chest syndrome. She improved on antibiotics without blood transfusions and was discharged in stable condition to complete a four-week course of oral clindamycin. Chart review revealed multiple missed appointments, and she has been lost to follow-up. DISCUSSION: This case highlights many important takeaways healthcare providers must consider when providing care to immigrant patients. Although three-quarters of newborns with sickle cell disease (SCD) are born in sub-Saharan Africa, there is a generous and underappreciated population affected within Latin America, where many developing countries lack newborn screening programs. In the U.S., providers often rely on newborn screening results, which over time has likely decreased our index of suspicion in older children for conditions we typically diagnose prenatally or in the newborn period. Despite multiple subspecialties being involved in this patient’s care, providers failed to consider SCD as a possible etiology despite early findings of anemia and a small spleen on CT scan. Although advancements in newborn screening, genetic counseling, and prenatal ultrasound have changed the prevalence and presentations of genetic and congenital disorders, we as providers must maintain a high index of suspicion. Additionally, fear of deportation, language barriers, limited financial resources, and low health literacy are some of the many barriers immigrant patients face when seeking care in this country. In this case, the family spoke French Creole; access to a language line was crucial. Providers must ensure families have an appropriate understanding of the disease process and address socio-cultural and economic concerns to prevent at risk children from being lost to follow-up.

Effectiveness of adjunctive clindamycin in β-lactam antibiotic-treated patients with invasive β-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study

Clindamycin is strongly recommended as an adjunctive treatment to β-lactam antibiotics in patients with severe invasive group A β-haemolytic streptococcal (iGAS) infections. However, there is little evidence of a benefit in the use of clindamycin in humans, and its role, if any, in treating patients with invasive non-group A/B β-haemolytic streptococcal (iNABS) infections is unclear. For this retrospective multicentre cohort study, we used a dataset from patients in the Cerner Health Facts database, which contains electronic health-based data from 233 US hospitals. We queried the Cerner Health Facts database for inpatients (no age restriction) admitted to hospital in 2000-15, with any clinical cultures positive for β-haemolytic streptococcal taxa of interest, and who had received β-lactam antibiotics within 3 days either side of culture sampling. This group of patients was then queried for those who had also received intravenous or oral clindamycin within 3 days either side of culture sampling. Patients were excluded if they had polymicrobial growth or clindamycin non-susceptible isolates, received linezolid, or had missing variable data needed for analysis. Patients were categorised by Lancefield group (iGAS or iNABS); β-lactam antibiotic-treated patients who had received clindamycin were propensity-matched (1:2) to those who did not receive clindamycin separately for iGAS and iNABS cohorts, and logistic regression was then used to account for residual confounding factors. The primary outcome was the adjusted odds ratio (aOR) of in-hospital mortality in propensity-matched patients treated with adjunctive clindamycin versus those not treated with clindamycin in the iGAS and iNABS infection cohorts. We identified 1956 inpatients with invasive β-haemolytic streptococcal infection who had been treated with β-lactam antibiotics across 118 hospitals (1079 with iGAS infections and 877 with iNABS infections). 459 (23·4%) of these patients had received adjunctive clindamycin treatment (343 [31·7%] patients with iGAS infections and 116 [13·2%] patients with iNABS infections). The effect of adjunctive clindamycin therapy on in-hospital mortality differed significantly and showed the opposite trend in iGAS and iNABS infection cohorts (p=0·013 for an interaction). In the iGAS cohort, in-hospital mortality in propensity-matched patients who received adjunctive clindamycin (18 [6·5%] of 277 patients) was significantly lower than in those who did not (55 [11·0%] of 500 patients; aOR 0·44 [95% CI 0·23-0·81]). This survival benefit was maintained even in patients without shock or necrotising fasciitis (six [2·6%] of 239 patients treated with adjunctive clindamycin vs 27 [6·1%] of 422 patients not treated with adjunctive clindamycin; aOR 0·40 [0·15-0·91]). By contrast, in the iNABS infection cohort, in-hospital mortality in propensity-matched patients who received adjunctive clindamycin (ten [9·8%] of 102) was higher than in those who did not (nine [4·6%] of 193), but this difference was not significant (aOR 2·60 [0·94-7·52]). Several subset analyses found qualitatively similar results. Real-world data suggest that increased use of adjunctive clindamycin for invasive iGAS infections, but not iNABS infections, could improve outcomes, even in patients without shock or necrotising fasciitis. Intramural Research Program of the National Institutes of Health Clinical Center and the National Institute of Allergy and Infectious Disease.